Cite
HARVARD Citation
Dulloo, S. et al. (n.d.). Comparison between 1st generation EGFR tyrosine kinase inhibitor (gefitinib) versus 2nd generation (afatinib) in EGFR-mutated non-small cell lung cancers (NSCLC) – real world experience. Lung cancer. pp. S42-S43. [Online].